Product image of Ituxredi (Rituximab) supplied by GNH India

Ituxredi

Active Ingredient:
Rituximab
Origin:
EU

Ituxredi (Rituximab)

Rituximab, the active ingredient in Ituxredi, is a monoclonal antibody presented as an intravenous solution for intravenous use. It targets CD20‑positive B‑lymphocytes and is employed in the treatment of certain cancers and autoimmune disorders in adult patients.

GNH India supplies Ituxredi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Reddy Holding Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ituxredi (rituximab) is indicated for diseases driven by CD20‑positive B‑cell activity.

  • Non‑Hodgkin lymphoma: induces remission by depleting malignant B‑cells.
  • Chronic lymphocytic leukemia: improves survival through B‑cell depletion.
  • Rheumatoid arthritis: reduces joint inflammation by targeting pathogenic B‑cells.
  • Granulomatosis with polyangiitis: controls vasculitis by eliminating autoreactive B‑cells.
  • Microscopic polyangiitis: achieves disease control through B‑cell suppression.

How It Works

  • Rituximab binds with high affinity to the CD20 antigen expressed on the surface of pre‑B and mature B‑lymphocytes. This binding triggers complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and direct apoptosis, leading to selective depletion of CD20‑positive B‑cells and modulation of immune responses in malignancy and autoimmunity.

Side Effects

Adverse reactions may occur with rituximab therapy and are categorized by frequency and severity.

Common Side Effects

  • Infusion‑related reactions: fever, chills, rigors, or hypotension during administration.
  • Infections: upper respiratory or urinary tract infections.
  • Cytopenias: transient neutropenia or thrombocytopenia.
  • Gastrointestinal upset: nausea, vomiting, or diarrhea.

Serious or Rare Side Effects

  • Severe infusion reactions: bronchospasm, angioedema, or anaphylaxis.
  • Hepatitis B reactivation in carriers.
  • Progressive multifocal leukoencephalopathy (PML).
  • Cardiac arrhythmias or myocardial infarction.
  • Severe infections such as sepsis.

Precautions & Warnings

Prior to initiating rituximab therapy, clinicians should assess patient history and monitor for potential complications.

  • Screen for hepatitis B: test for HBsAg and anti‑HBc before treatment.
  • Evaluate infection risk: treat active infections before infusion.
  • Monitor blood counts: perform baseline and periodic CBC.
  • Assess cardiac status: caution in patients with recent myocardial infarction.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Rituximab may interact with other agents that affect immune function or increase infection risk.

Major Interactions (Avoid)

  • Live vaccines: contraindicated during and for several months after therapy.
  • Concurrent chemotherapy agents that cause profound immunosuppression.

Moderate Interactions (Monitor Closely)

  • Antiviral prophylaxis (e.g., acyclovir) when hepatitis B risk is present.
  • Immunoglobulin replacement therapy: may reduce rituximab efficacy.
  • Corticosteroids: may augment immunosuppression, requiring infection surveillance.

Frequently Asked Questions

Ituxredi contains rituximab, a monoclonal antibody indicated for CD20‑positive B‑cell malignancies such as non‑Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases including rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Rituximab binds to the CD20 antigen on B‑lymphocytes, initiating complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and direct apoptosis. This selective depletion of CD20‑positive B‑cells reduces malignant cell populations and modulates autoimmune activity.

The dosage of Ituxredi is individualized by the prescribing clinician based on the specific indication, patient weight, disease severity, and treatment protocol. Healthcare providers determine the appropriate infusion schedule and amount.

Safety data for rituximab in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women should discuss reproductive plans with their healthcare professional.

To request Ituxredi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Ituxredi (rituximab) is a chimeric monoclonal antibody, whereas newer agents like obinutuzumab are humanized or fully human. Differences may include infusion duration, immunogenicity, and efficacy in specific subpopulations, but clinical choice depends on approved indications, physician experience, and patient factors.

Ituxredi must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking to maintain product stability.

Ituxredi is supplied as an intravenous solution and is administered by a qualified healthcare professional through an IV infusion. The infusion rate is typically started slowly and may be increased based on patient tolerance and protocol guidelines.

Serious risks include severe infusion reactions (anaphylaxis, bronchospasm), hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), and life‑threatening infections. Patients should be monitored closely during and after infusion for any signs of these complications.

Ituxredi is contraindicated in patients with known hypersensitivity to rituximab or any component of the formulation, and in those who have received live vaccines within four weeks of treatment. Caution is also advised for individuals with active severe infections or uncontrolled cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Rituximab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT